Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
NCT07599982
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily insulin injections (MDI), or with type 2 diabetes (T2D) who use MDI, basal insulin only, or who are candidates to initiate basal insulin, in conjunction with continuous glucose monitoring (CGM).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 1 Diabetes (T1D)
- Type 2 Diabetes (T2D)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- DreaMed Diabetes
- Last updated on ClinicalTrials.gov
- August 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- Henry Ford Health System · Detroit, MI
New York · 1
- SUNY Upstate Medical Center · Albany, NY
North Carolina · 1
- Centricity Research - Morehead City · Morehead City, NC
Texas · 1
- Texas Diabetes & Endocrinology · Austin, TX
Utah · 1
- Diabetes & Endocrine Treatment Specialisits (DETS) · Sandy City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.